CytoDyn Total Liabilities 2010-2024 | CYDY

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

CytoDyn total liabilities from 2010 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

CytoDyn total liabilities from 2010 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$80.4B
Zoetis (ZTS)	$70.5B
Takeda Pharmaceutical (TAK)	$44.1B
Daiichi Sankyo, - (DSNKY)	$43.3B
Sandoz Group AG (SDZNY)	$20.6B
Merck (MKKGY)	$18.5B
Astellas Pharma (ALPMY)	$17.5B
Summit Therapeutics (SMMT)	$17B
United Therapeutics (UTHR)	$16.4B
Shionogi (SGIOY)	$12.3B
Neurocrine Biosciences (NBIX)	$11.6B
Orion OYJ (ORINY)	$7.7B
Madrigal Pharmaceuticals (MDGL)	$7.7B
Corcept Therapeutics (CORT)	$6.8B
Hikma Pharmaceuticals Plc (HKMPF)	$6.2B
Stevanato Group S.p.A (STVN)	$6.2B
Ionis Pharmaceuticals (IONS)	$5.2B
Grifols, S.A (GRFS)	$5.2B
Ono Pharmaceutical (OPHLF)	$4.7B
Recursion Pharmaceuticals (RXRX)	$4B
Crinetics Pharmaceuticals (CRNX)	$3.4B
Catalyst Pharmaceuticals (CPRX)	$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.4B
Centessa Pharmaceuticals (CNTA)	$2.2B
Hypermarcas (HYPMY)	$2.2B
Soleno Therapeutics (SLNO)	$2B
BioCryst Pharmaceuticals (BCRX)	$1.9B
NewAmsterdam Pharma (NAMS)	$1.8B
Evotec AG (EVO)	$1.6B
Dyne Therapeutics (DYN)	$1.4B